This retrospective study had as main objective to study the incidence of chemotherapy-induced amenorrhea in young women (<45 years) treated for early breast cancer, and to analyze the different epidemiological, clinical, pathological and therapeutical aspects of breast cancer in young women.From January 2009 to December 2011, 104 cases of breast cancer in young women aged 45 and under, were recruited at the Medical Oncology department of the MOHAMMED VI Teaching Hospital of Oujda.Early Breast cancer incidence in young women (<45 years) in our study was 10.97% of the total number of breast cancer. The average age of our patients was 38.05 years, with extremes of 24 and 44 years.The most common mode of revelation was self-examination of breast nodule (with or without other signs) found in 96% of cases. Concerning the histology, invasive ductal carcinoma was the most frequent noted in 90.4% cases, the SBR III grade was noted in 18% of cases, and SBR II in 77% of cases when the SBR grade I represents only 5% of cases. Histological node involvement was found in 44.2% patients, vascular emboli were noted in 57.7% of cases, while hormone receptors were positive in 77.9% cases.Therapeutically, 98 patients received adjuvant chemotherapy preceded by a conservative or radical breast surgery.In our series, 77 of our patients had chemotherapy-induced amenorrhea (CIA), 34 of them after the third treatment, 26 patients had a final chemotherapy-induced amenorrhea, while the return of menses was recorded in 51 patients (16 patients with return of regular cycles and 35 patients with return of irregular cycles) with an average of 12.33 months and extremes of between 6 and 36 months. Hot flashes were the most common symptom 90%.Ages above 40 years was predictive of installation of the chemotherapy-induced amenorrhea (95.7%) in our study (p <0.05).All women who presented a final CIA were aged> 40 years.Among women with an age <35 years, 3 of them showed CIA, and all three have recovered regular cycles.The rate of CIA observed in patients who received anthracyclines and alkylating was 93.5% (AC protocol 60 or FEC100).The observed CIA rates among patients who received taxanes (paclitaxel or docetaxel) was 39%. In our series, 3 cases of pregnancy were recorded in patients who have had an CIA